Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Unresectable liver metastases secondary to colorectal cancer~  * Less than 70% liver involvement on CT scan or MRI~ * Liver biopsy required before study unless 1 of the following conditions are met:~    * Carcinoembryonic antigen greater than 30~   * 5 or more liver metastases visible on CT scan or MRI~   * Greater than 50% to under 70% liver involvement on CT scan or MRI~* Histologically proven primary colorectal cancer that is resected or appears resectable on CT scan and physical exam~  * Documentation of previously resected primaries must be based on pathologic results of the resected tumor~ * Histological documentation of synchronous disease must be based on 1 of the following:~    * Biopsy of primary colorectal tumor before study~   * Suspicious lesion on barium enema, colonoscopy, or sigmoidoscopy, and a liver biopsy positive for adenocarcinoma consistent with the primary colorectal tumor~* Measurable disease~  * Clearly defined liver mass measuring at least 2 cm or at least 3 liver masses on CT scan or MRI~* No evidence of extrahepatic disease on CT scan and physical exam~* No portal vein occlusion or ascites~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Hepatic:~* Bilirubin no greater than 2 times normal~Other:~* No other malignancy within the past 5 years except inactive nonmelanomatous skin cancer, carcinoma in situ of the cervix, or grade 1 bladder cancer~* Not pregnant or nursing~* Fertile patients must use effective contraception~Chemotherapy:~* At least 1 year since prior adjuvant chemotherapy comprising fluorouracil (5-FU) and leucovorin calcium (CF) or 5-FU, CF, and levamisole (LEV)~* At least 6 months since prior adjuvant chemotherapy comprising 5-FU with or without LEV~* No other prior chemotherapy~* No other concurrent chemotherapy~Endocrine therapy:~* No concurrent hormonal therapy except for nondisease-related conditions, e.g.:~  * Steroids for adrenal failure~ * Insulin for diabetes~ * Intermittent dexamethasone as an antiemetic~Radiotherapy:~* No prior radiotherapy to the liver

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I - laparotomy + conventional surgery + chemotherapy (Type: EXPERIMENTAL): Patients undergo laparotomy for placement of a hepatic artery catheter and then subcutaneous placement of a hepatic artery infusion pump. Patients with unresected primary disease also undergo resection at the time of catheter and pump placement. Beginning within 1-2 weeks after surgery, patients receive floxuridine, dexamethasone, and leucovorin calcium (CF) via continuous hepatic artery infusion on days 1-14. Treatment for patients continues every 4 weeks in the absence of disease progression or unacceptable toxicity.~Quality of life and medical resource utilization are assessed at baseline, every 3 months for 1 year, and then at 18 months.~Patients are followed every 3 months.
- Arm II - conventional surgery + chemotherapy (Type: EXPERIMENTAL): Patients receive CF IV and fluorouracil IV on days 1-5. Patients with unresected primary disease undergo resection within 3-4 weeks before initiation of chemotherapy.~Treatment for patients continues every 4 weeks in the absence of disease progression or unacceptable toxicity.~Quality of life and medical resource utilization are assessed at baseline, every 3 months for 1 year, and then at 18 months.~Patients are followed every 3 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).